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Abstract
Background Costs of chronic wound care are significant,
but systematic reviews of cost-effectiveness studies
regarding guideline-based or strategic interventions are
scarce.
Objectives Our objectives were to assess/compare the
cost effectiveness of new interventions/systems designed to
improve the prevention/treatment of chronic wounds in
adult populations against current care and provide decision
makers with information on which to base future inter-
ventions for chronic wound management.
Data Sources Data sources included PubMed, Scopus,
HTA, and NHS EED.
Study Eligibility Criteria, Participants, and Interven-
tions We included comparative health economic evalua-
tions of interventions published in English designed to
prevent or treat adult chronic wounds that were guideline-
based or strategic in nature and from which an incremental
cost-effectiveness ratio or incremental net health benefit
was reported or could be calculated.
Study Appraisal and Synthesis Methods Study and model
characteristics and outcomes were extracted into pre-
designed tables. Quality assessment of studies was based
on literature-reported methods. Studies were assigned
strength of evidence ratings and recommendation level for
decision makers.
Results A total of 16 health economic evaluations were
included, of which ten were trial based and six were
wholly model based. Only three studies had high, and five
studies moderate, strength of evidence and were recom-
mended for decision makers. All studies had some short-
comings regarding time horizon, costs, effectiveness units,
and methodological reporting. Two studies had major
flaws.
Limitations Limitations include missed studies published
in non-English languages or not cited in searched dat-
abases; judgment bias in assessing studies.
Conclusions and Implications of Key Findings Few well
conducted cost-effectiveness studies exist to guide decision
makers regarding guideline-based or strategic interventions
for chronic wounds.
Key Points for Decision Makers
Few good economic studies exist quantifying the
cost effectiveness of strategic or guideline-based
interventions in regard to chronic wound
management.
The strongest evidence is for prevention and
treatment of diabetic foot ulcers, prevention of
pressure ulcers in long-term care settings, and
treatment of patients with critical limb ischemia.
Clinical practice guidelines are proliferating in the
field of chronic wound care, but large gaps exist in
demonstrating their cost effectiveness.
Systematic Review Registration Number: CRD42013005606
(PROSPERO).
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1 Introduction
Chronic wounds are those wounds that fail to heal in a
timely manner or become stuck in the inflammatory phase
of healing [1]. In developed countries, the incidence of
chronic wounds has been growing in recent years and
likened to a ‘silent epidemic’ [2]. The increase in the
incidence of chronic wounds is due to both the aging of
populations (longer lifespan) and the concurrent increase in
comorbidities, such as diabetes, obesity, venous hyperten-
sion, and peripheral vascular disease [2, 3].
The most common types of chronic wounds—venous
leg ulcers (VLUs), diabetic foot ulcers (DFUs), and pres-
sure ulcers (PUs)—and their current treatments often mean
that employed patients cannot work until their wounds are
healed. For example, individuals with DFUs are often
forced to change their nature of employment or take time
off work, and can become disabled and unable to work [4].
Social contact and mobility are also frequently impacted,
leading to decreased quality of life [5]. While in the last
two decades advanced therapeutics have been developed as
adjunct treatments, the level of evidence for their efficacy
is often poor, as exemplified by a recent review of
advanced VLU treatments conducted by researchers at The
Johns Hopkins University Evidence-Based Practice Center
[6]. Most importantly, even though many guidelines for the
management of chronic wounds have been published
(clinical practice guidelines [CPGs]), too many patients
still do not receive the fundamental wound care and
treatment described in the guidelines. According to one
professional group examining the problem for VLUs
(Group IV of the Pacific Vascular Symposium 6), there are
too many guidelines on VLUs from too many sources;
coordinated integration is difficult; and most critically,
there is a need to unify evidence-based guidelines to
facilitate implementation [7].
No one knows the true cost of treating chronic wounds
worldwide, because country-wide surveys have not been
undertaken. However, those costs are likely to be very
substantial. In the UK, costs in 2005–2006 prices were
estimated at £2.3–3.1 billion [8] and more recently in the
USA at $US6–15 billion [9], although, in 2010, Driver
et al. [10] reported that, in the USA alone, the cost of
treating DFUs was $US39 billion. To help guide healthcare
providers in the management of chronic wound care, health
economics studies are available, but there are considerable
limitations with many of these studies [11, 12]. Besides
flaws in the health economic studies themselves (e.g. short
horizon times, questionable model inputs, or incomplete or
poorly structured models), in the field of wound care such
studies are mostly concerned with basic wound care and
advanced therapies rather than examining the costs and
benefits of applying a broader strategic treatment pattern.
Consequently, little thought seems to have been given to
the implementation and actual testing of CPGs in practice,
particularly from a cost-effectiveness point of view [13].
Because examination of CPGs and strategies to improve
cost effectiveness in wound care has been poorly explored,
this is the subject of this systematic review.
The objective of this systematic review, therefore, is to
assess the cost effectiveness of new interventions or sys-
tems designed to improve the prevention or treatment of
chronic wounds in adult populations by comparing existing
systems or practices. A second objective is to provide
decision makers with information on which to base future
interventions for chronic wound management.
2 Methods
2.1 Study Inclusion/Exclusion Criteria
Studies were eligible for consideration if they
• Were health economic evaluations (cost-benefit, cost-
effectiveness, or cost-utility analyses)
• Described interventions that prevented a chronic wound
from occurring or treated an existing chronic wound
• Compared guideline-based or strategic interventions
with an existing practice (i.e. change of practice)
• Included at least one incremental cost-effectiveness
ratio (ICER) or incremental net health benefit (INHB),
or provided costs and benefits so that ICERS/INHBs
could be calculated
• Used any time horizon
• Were published in English.
Studies were excluded if they were
• Cost-minimization studies
• Only described by abstracts, letters, or editorials
• Studies that described a purely product- or technically
oriented intervention, such as testing of a device, drugs,
dressing, or bandaging in the context of chronic wounds.
2.2 Literature Sources
Databases were searched from 1 January 1974 to 20 August
2013 for eligible studies in using the following text strings:
(‘wound’ OR ‘wounds’ OR ‘wound care’ OR ‘ulcer’ OR
‘ulcers’) AND (‘cost-effectiveness’ OR ‘cost-benefit’ OR
‘cost-utility’ OR ‘economic evaluation’ OR ‘economic
model’ OR ‘decision model’ OR ‘decision tree’). The fol-
lowing databases were searched: PubMed, Scopus, Health
Technology Assessment (HTA), and National Health Ser-
vice Economic Evaluation Database (NHS EED).
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While the initial selection of studies was made using
abstracts based on the inclusion/exclusion criteria, the final
selection (and rejection of any studies) was made after
reading the full text. Reviews and systematic reviews rel-
evant to the objectives of the study were also searched for
other possible studies.
2.3 Study Classification
Studies accepted for the systematic review were differen-
tiated according to whether cost and effectiveness com-
ponents (model or calculation inputs) were derived from a
single clinical trial or study designed as part of the eco-
nomic study (trial-based economic studies), or synthesized
from numerous studies (modeled economic studies). If
studies used a single clinical trial and modeling, they were
still classified as trial-based studies. The rationale for this
classification is that trial-based studies are likely to reflect a
specific situation or setting but could have issues in gen-
eralization to other settings. Model-based studies under this
classification are likely to reflect broader situations or
settings due to more diverse model inputs, but could have
larger uncertainties.
2.4 Data Extraction
Outcomes were extracted from included studies and
transferred to pre-designed tables describing key patient
and wound characteristics and ICERs/INHBs (trial-based
economic studies) or model parameters and ICERs/INHBs
(modeled economic studies). If ICERs/INHBs were not
explicitly stated, these were calculated from the study data
using the general approach of cost of strategy A—cost of
strategy B/benefit of strategy A—benefit of strategy B.
2.5 Quality Assessment of Studies
Quality assessment of studies was based on a synthesis of
the consensus health economic criteria (CHEC) list devel-
oped by Evers et al. [14] and the quality assessment tool for
decision-analytic models created by Philips et al. [15] as
defined in the 23-item study appraisal reported by Langer
and Rogowski [16]. The only modifications made to this
study appraisal were as follows. (i) The third question in the
Outcomes section (directed toward trial-based economic
studies) was changed to ‘‘Were outcomes appropriately
incorporated into models and adequately described?’’ This
change pertained to meta-analytical synthesis of outcomes,
and none of the trial-based studies used meta-analysis. (ii)
The second question in the Analysis section was scored as
follows: (a) short-term horizons (B12 months): no dis-
counting of costs/benefits = 1; discounting of any costs/
benefits or not stated = 0; (b) longer time horizons
([12 months): appropriate discounting of costs and effects
= 1; partially appropriate discounting = 0.5; no discounting
or not stated = 0. (Original scoring was as follows: (a) short
time horizon (B12 months): not applicable; discounting of
costs and effects = 1; only costs/not motivated discount rate
= 0.5; discount rate not stated = 0.)
Summary scores for each study were calculated
(method: Table 1) but were not used per se in any sub-
sequent weighting scheme; rather, study scores and the
possible score range were developed to provide a sense of
whether the checklist questions could be answered in full
or partially answered in each section, whether some
questions could be answered partially, or whether only few
questions could be answered at all.
Each study was given a strength-of-evidence rating as
used in the GRADE (Grades of Recommendation,
Assessment, Development, and Evaluation) approach [17]
and defined as follows: high (further research is very
unlikely to change confidence in the estimate of the effect);
moderate (further research is likely to have an important
impact on confidence in the estimate of the effect and may
change the estimate); low (further research is very likely to
have an important effect on confidence in the estimate of
the effect and is likely to change the estimate); and very
low (any estimate of effect is very uncertain). In the con-
text of the GRADE category definitions, effect in this
systematic review means the ICER or INHB.
These ratings were assigned based on how questions
were scored in each section of the quality assessment,
additional strengths or weaknesses of the study that the
quality assessment did not cover, and the overall strength
of the underlying evidence. An example of an additional
strength might be that the study employed meta-analysis
from several appropriate sources to derive realistic wound
healing outcomes; an example of an additional weakness
might be that a model was not validated. The overall
Table 1 Scoring system used to identify strengths and weaknesses in








a 5 for trial-based economic analysis and 6 for model-based eco-
nomic analysis
b 0–2 for trial-based economic analysis not using a model, and 0–5
for all others
c 17 for trial-based economic analysis (no modeling), 20 for trial-
based economic analysis (modeling included), and 22 for model-
based economic analysis
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strength of the evidence is a judgment, not only about the
quality of the design of the study but also the robustness
and nature of the study data (input), the study results, the
uncertainty surrounding those results, and therefore whe-
ther or not the conclusions are credible.
Use of each study for decision making was categorized
as recommended or not recommended depending on whe-
ther the study had a high or moderate strength of evidence,
and had credible and robust results for the intervention
described. Recommended studies can have contextually
positive or negative results—for example, the study could
be given a recommendation that decision makers take note
of the conclusions because the results suggest that the
intervention is not likely to be cost effective.
The systematic review protocol was registered with




The primary search yielded 2,789 citations. A review
located from the literature search, which was conducted by
Franks and Bosanquet [18], yielded four additional cita-
tions, which were evaluated using full text. A total of 16
studies were included in the systematic review, with six
studies rejected at the full-text assessment stage mainly due
to inability to calculate an ICER or INHB (Fig. 1; Table 2).
The results of the quality assessment are shown in
Online Resource 1.
3.1 Overview
Ten of the studies were trial-based economic studies, of
which seven did not use models (Table 3) while six studies
were model-based economic studies (Table 4). Strength of
the evidence varied considerably for the trial-based studies,
with only one study assessed as high and three as moderate;
two model-based studies were assessed as having a high
strength of evidence, while two others had a moderate
strength of evidence.
Because the designs of the studies were so heteroge-
neous, meta-analysis was not possible, so each study is
assessed in detail.
3.2 Trial-Based Economic Studies (No Modeling)
3.2.1 Simon et al. (Strength of Evidence: Moderate;
Recommended)
The goal of the comparative before-and-after design study
reported by Simon et al. [25] was to compare current leg
ulcer care at one district in the UK (Stockport) in 1993 with
the introduction of five leg ulcer clinics in 1994, which
used nurses trained in wound care evidence-based treat-
ments focused on vascular screening and multilayer ban-
daging. Three-month data-collection periods (audits) were
carried out in both years, using the nearby district of
Trafford as a contemporary control. The proportion of leg
ulcers healed in 1994 versus 1993 (3 months) was 42 vs.
26 %, with healing rates at Trafford of 20 and 23 %,
respectively. Although detailed costs were calculated and
extrapolated in each year, no specific ICER was reported;
by extrapolating wound healing data for 1 year, an ICER of
-£1,186/additional healed ulcer was obtained through
calculation. Principal weaknesses of the study included
lack of sensitivity analysis, exclusion of more severe leg
ulcers, and characteristics of the study populations, making
comparison with other districts within the UK or other
countries difficult. Strengths of the study included reduc-
tion of selection bias by using a geographic catchment area
and the study design itself.
3.2.2 Morrell et al. (Strength of Evidence: Moderate;
Recommended)
Morrell et al. [26] utilized a non-blinded randomized
controlled trial (RCT) in which patients with VLUs were
randomly assigned to community leg ulcer clinics that
used four-layered bandaging or usual care provided by
district nurses in the UK. Using a time horizon of 1 year
and presumably a healthcare payer’s perspective, results
showed an ICER of £2.36 per ulcer-free week (presumed
95 % confidence interval [CI] -31.94–99.12), obtained
through bootstrap resampling. The authors noted poor
healing rates (34 % of wounds healed at 12 weeks in the
intervention group vs. 24 % in the control group), sug-
gesting this was due to larger and older ulcers at base-
line. While a factor, later results of the landmark RCT
‘venUS I’ [42] suggest that lack of expertise in four-
layer bandaging could have played a role. Strengths of
the study were that the sample size was appropriate and
the population selected fairly representative of the ‘real
world’. Weaknesses included some uncertainty of cost
savings due to lack of transparency in data sources and
reporting.
3.2.3 Thomson et al. (Strength of Evidence: Very Low;
Not Recommended)
A pilot study conducted by Thomson and Brooks [27]
focused on a projected PU prevention policy in a 252-bed
geriatric unit in Glasgow (Scotland) in which current care
was compared with a PU prevention policy, although
details of the new program were scant. Although no ICERs
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or INHBs were reported, calculations showed that cost
savings of £7,717 would be achieved for every averted PU.
Weaknesses of the study included lack of program details,
no patient population description, lack of sensitivity ana-
lysis, and lack of credible data used to develop PU prev-
alence in the ‘program’ arm.
3.2.4 Ohura et al. (Strength of Evidence: Low; Not
Recommended)
This Japanese study [28, 29] was carried out in a hospital
setting to examine the cost effectiveness of three different
strategies to treat stage II and III PUs: (i) modern dress-
ings and standardized wound management, and traditional
dressings (ii) with and (iii) without standardized wound
management. Wound healing assessment was character-
ized using the Pressure Sore Status Tool (PSST) with a
cohort of 83 patients over a period of 12 weeks. Based on
costs and healing results, the ICER comparing strategies
(i) and (iii) was -$448 per PSST point reduction, with
strategy (i) being dominant. Weaknesses of the study
included the small sample size, lack of explicit perspec-





























(n = 2789) 
Records excluded  
(n =2377) 
Articles assessed for 
eligibility 
(n = 22) 
Full-text articles 
excluded with reasons 
(n = 6) 
Studies included in 
qualitative synthesis 
(n = 16) 
Fig. 1 Flow chart for study
selection
Table 2 Studies rejected for the systematic review
Study Reason for rejection
Bosanquet et al. [19] Insufficient healing data to calculate INHB
Kerstein and Gahtan [20] Costs/benefits not clearly indicated for the two different settings (home healthcare vs. office)
Kerstein et al. [21] Study evaluated three different dressings (i.e. not strategic intervention)
Quioc [22] Case study of two patients
Ellison et al. [23] Insufficient data to calculate INHB
Schuurman et al. [24] Cost minimization study; insufficient data to calculate INHB
INHB incremental health benefit
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3.2.5 Gordon et al. (Strength of Evidence: Low; Not
Recommended)
A similar albeit smaller trial to the one conducted by
Morrell et al. [26] was conducted by Gordon et al. [30], in
which participants with VLUs were randomized to either
the Lindsay Leg Club Model or home (visit) community
care in Australia; the Leg Club Model is an informal social-
interactive-promotional setting in which patients receive
care similar to traditional home care once a week. From a
‘collective’ perspective, equivalent to a societal perspec-
tive, at 6 months the incremental cost per healed ulcer was
(in Australian dollars [$A]) $A515 and $A322 per reduced
pain score, reflecting improved healing rates and reduced
pain scores in the Leg Club patients. From a healthcare
provider perspective, costs were always less and patients
had higher healing rates at 3 and 6 months for the Leg Club
group than for the control group. Weaknesses of the study
included the short time horizon, lack of healing and pain
data, small sample size, awkward benefit units, and no
consideration of healing rate changes in the sensitivity
analysis. A strength of the study was that some community
and patient costs were assessed.
3.2.6 Vu et al. (Strength of Evidence: Moderate;
Recommended)
Vu et al. [31] conducted an unusual pseudo-randomized
pragmatic cluster trial of 342 VLUs and PUs in 176 elderly
residents of 44 high-care nursing homes to determine
whether introduction of a multidisciplinary wound care
team was cost effective compared with usual care over a
period of 20 weeks. Adjusted time-to-heal analysis showed
that wounds healed faster in the intervention group than in
the control group, by 36.5 days. Combined with cost-result
data, calculations showed a dominant ICER of $A-53.3
per ulcer-free week gained. Net benefits and their 95 % CIs
were always positive for any non-negative societal will-
ingness to pay (WTP) for a day without a chronic wound.
Weaknesses of the study included lack of cost details,
while strengths of the study included sample size, the
methods used to analyze the data adjusting for clustering
effects, and the WTP results. The study would also have
benefitted from further sensitivity analysis.
3.2.7 Sanada et al. (Strength of Evidence: Low; Not
Recommended)
Using a cohort design, Sanada et al. [33] in Japan evaluated
the cost effectiveness of a new incentive strategy based on
the structural element of the Donabedian model [43] for PU
management in hospitals, which was recently introduced
by the Government. The incentive reimburses about $US45
per admission of a patient judged at high risk for a PU if
the hospital meets certain facility criteria and the intro-
duction of full-time trained wound ostomy continence
nurses as part of multidisciplinary teams to manage PUs.
Patients were compared in institutions in which the new
incentive had been implemented versus institutions in
which it had not been implemented (105 patients, 59
institutions). Outcomes were based on the Depth, Exudate,
Size, Infection, Granulation, Necrosis (DESIGN) score, a
tool for classifying PU severity and monitoring progression
towards healing, which is used almost exclusively in Japan
[44]. At 3 weeks, the cost effectiveness was ¥14,272
(equivalent to $US143 in 2013) per 1-point reduction in the
DESIGN score. Weaknesses of the study included an
unstated perspective; lack of detailed resource utilization,
unit costs, and reference year for non-labor costs; incom-
plete reference to data sources; potential for missing certain
material and procedure costs; no sensitivity analysis for
critical variables; small sample size and associated uncer-
tainty of having fewer than two patients per site; and the
generalizability of the cost-effectiveness results, as the
DESIGN score is not used outside of Japan.
3.3 Trial-based Economic Studies (Modeling)
3.3.1 Harris and Shannon (Strength of Evidence:
Very Low; Not Recommended)
In a retrospective chart review of patients with a variety of
wound types in Ontario, Canada, Harris and Shannon [32]
conducted a cost-effectiveness study to determine if man-
agement of wounds was more cost effective when there
was involvement of nurses with enterostomal (ET) or
advanced wound ostomy skills (AWOS). A probabilistic
decision analysis and Monte Carlo simulation was per-
formed between the purely ET/AWOS group and a hybrid
group in which patients were treated initially by an ET/
AWOS nurse followed by general visiting nurses (regis-
tered nurses and registered practical nurses), suggested that
nursing visit cost is higher for the hybrid model. Com-
paring patients treated by ET/AWOS nurses with those
treated in a hybrid model showed a dominant ICER of
$Can-922 per ulcer-free week. Moreover, there was a
significant difference in healing time and reduced costs as
ET/AWOS nurses became more involved with cases.
Weaknesses of the study included the lack of stated per-
spective and time horizon, detailed reporting of resources
utilized and unit costs, additional costs besides nursing,
description of the decision tree, missing data (bias issues),
and the nature of the data drawn retrospectively from chart
reviews.
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3.3.2 Makai et al. (Strength of Evidence: Low; Not
Recommended)
Another initiative in the Netherlands concerned PUs in
nursing and residential care homes in an elderly population
aged 80 years or more and whose projected lifespan was
short, as evidenced by the mortality rate of 30 % over
1 year [34]. The prospective pre–post cohort design aimed
to determine the cost effectiveness of replacing usual care
with a Dutch quality improvement collaborative (QIC) in
25 organizations. The QIC has the goal of reducing the
prevalence and incidence of PUs by increasing evidence-
based prevention measures, including risk assessment;
involvement of patients/family; use of better mattresses;
preventing nutritional deficiency; and reducing non-useful
measures, such as massage, 90 turns every 4 h, and use of
topical agents to prevent blood supply disturbances caused
by pressure. Information on prevalence, incidence, and
severity of PUs was collected 1 month prior to QIC
implementation, which occurred in stages. Post-QIC data
were collected on 88 selected patients in round 3. The
healthcare perspective was employed, with a horizon time
of 2 years, modeling three scenarios projected from 1 year
of data: totally sustained initiative; partially sustained; and
not sustained. A Markov model including ten health states
was built for an intervention arm and a standard of care
group (no initiative). A probabilistic sensitivity analysis
was also conducted using Monte Carlo simulations. ICERs
varied from €78,517 per quality-adjusted life-year (QALY)
in which the initiative was completely sustained to
€131,253/QALY where it was not sustained at all. The
probability of the ICER being below €80,000—the Dutch
benchmark for cost-effective interventions on patients with
high disease severity—was only 50 % for the totally sus-
tained scenario, casting doubt on whether the intervention
is viable. Weaknesses of the study included lack of details
for the Markov model as well as lack of validation/cali-
bration, the rather strange probabilistic sensitivity analyti-
cal results, uncertainty over reference year for all costs, and
the relatively small sample size.
3.3.3 Shannon et al. (Strength of Evidence:
High; Recommended)
Shannon et al. [35] tested the prevention effectiveness of a
new PU prevention program that followed evidence-based
guidelines, standardized products, and the Minimum Data
Set (MDS)-2.0 versus existing care in two nursing and
rehabilitation centers. Medicare-eligible patients at risk of
developing a PU were randomized to the new program or
existing care and followed for a maximum of 6 months. A
modified activity-based costing method tracked labor,
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health states) was used in conjunction with a one-way
sensitivity analysis to evaluate costs and benefits. Although
ICERs or INHBs were not stated by the authors (results
focused on cost savings), calculations showed that a cost
savings of $US3,715 could be expected for each averted
PU. The only weaknesses of the study were missing unit
costs and the fact that the study is only applicable to res-
idents at moderate or high risk of developing a PU.
Strengths of the study include the study design itself as
well as appropriate statistical power; and the credibility of
the decision analytic model and the data sources used and
the cost calculation methods.
3.4 Model-Based Economic Studies
3.4.1 Ortegon et al. (Strength of Evidence:
Moderate; Recommended)
Ortegon et al. [36] developed a risk-based Markov model
with 13 health states to answer the question of whether
adopting international standards to prevent and treat DFUs
versus current Dutch care was cost effective over a
patient’s lifetime. The perspective was that of the health-
care provider. The new strategy included intensive glyce-
mic control (IGC) and optimal foot care based on outcome
data drawn from key UK and Swedish studies, as well as
others. Model results were robust to changes in costs and
utility weights but sensitive to the amount of optimal foot
care employed concurrent with IGC. For example, with
10 % foot lesion reduction, the ICER was $US24,556/
QALY (year 1997 values) but only $US7,860/QALY when
90 % of foot lesion reduction was accomplished. IGC by
itself had an ICER of $US32,057/QALY. For most sce-
narios, the authors concluded that the intervention was cost
effective, with reductions in DFUs and lower extremity
amputations. Weaknesses of the study included no
description of current Dutch care; lack of detailed reporting
regarding cost components, unit costs, and resource utili-
zation; and lack of model calibration, face and internal
model validity, and cross-model validity. Strengths of the
study included meticulous model structure, assumptions,
model inputs, and external validation of the model; and the
exceptional care taken to model the Dutch population.
3.4.2 OPUMT (Strength of Evidence:
High; Recommended)
The Ontario Pressure Ulcer Model Team (OPUMT) was
given the task of evaluating implementation of PU pre-
vention strategies in addition to existing care in Ontario
long-term care facilities [37]. Five additional strategies
were analyzed: (i) alternate foam mattresses to replace
standard mattresses; (ii) adding 4-hourly turning/
repositioning for residents at high risk of developing PUs
and not currently on such a schedule in addition to alter-
nating foam mattresses; (iii) nutritional supplementation;
(iv) skin care protocol for incontinence; and (v) slightly
more than doubling registered nurse time per day for res-
idents at high risk of developing PUs. A risk-based Markov
model (high/low risk) with 52 health states was employed
with 1-week cycles for elderly residents with a mean life
expectancy of 3 years after admission; hospitalization or
death from PU-related or non-PU-related causes were
included. Data from several large Canadian databases and
multiple studies from the literature were used as model
inputs, the most important of which were also subject to
probabilistic sensitivity analysis. Strategies (i) and (ii) were
reasonably cost effective ($Can6,328 and $Can5,234/
QALY), but all other strategies were not, with
ICERs [$Can250,000/QALY. The only weaknesses of the
study were statement of year for some component costs,
and some calibration and internal validity model details; no
model cross-validation was performed. Strengths of the
study included meticulous selection/calculation of model
inputs from many sources, including large relevant pro-
vincial databases, a detailed and appropriate model, and
appropriate resource utilization.
3.4.3 Padula et al. (Strength of Evidence: Low; Not
Recommended)
In the USA, Padula et al. [38] modeled a guideline-based
PU prevention strategy versus standard of care for 1 year
for patients admitted to an acute care hospital with cost
effectiveness extrapolation to the remaining lifespan of
patients. A semi-Markov model utilizing seven health
states was compiled using the societal perspective. In the
intervention arm it was assumed that all patients experi-
enced strict adherence to WOCN guidelines with financial
investment, although details of these guidelines and what
constitutes standard of care were absent. A dominant result
of $US-1,463/QALY was found in favor of the interven-
tion arm. A major weakness of the study was extrapolation
of the model to lifetime results without additional hospi-
talization episodes. Other weaknesses included missing
unit costs and quantities and lack of model calibration/
validation.
3.4.4 Pham et al. (Strength of Evidence: High;
Recommended)
Pham et al. [39] were also interested in preventing PUs but
in the setting of long-term care facilities in which the mean
age of the patients was 83 years with a life expectancy of
2.8 years. Current prevention practice was compared
against four strategies: (i) pressure redistribution, (ii) oral
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nutritional supplements, (iii) skin emollients, and (iv) foam
cleaning, with (ii) through (iv) applied to residents at high
risk for PU development. The perspective was that of a
healthcare provider. Using a Markov model built by
OPUMT [37], with patients stratified by age, risk status,
wound status, local or systemic infection, and care setting,
they modeled each strategy against current practice.
Because the increase in QALYs was minimal, the authors
reported results in quality-adjusted life-days (QALDs);
(i) $Can-371/QALD; (ii) $Can24,367/QALD; (iii)
$Can218/QALD; and (iv) $Can-895/QALD. Strategies
(i) and (iv) were determined to be cost effective. Weak-
nesses of the study included some calibration and internal
validity model details; no model cross-validation was
performed. Strengths of the study included good selection/
calculation of model inputs from many sources, a detailed
and appropriate model, and appropriate resource
utilization.
3.4.5 Barshes et al. (Strength of Evidence: Moderate;
Recommended)
Barshes et al. [40] embarked on calculating cost effec-
tiveness for patients with critical limb ischemia (CLI;
typically Rutherford 5; the majority of patients would have
DFUs) over 10 years from a societal perspective based on
five different strategies to treat the CLI. The strategies were
(i) local wound care (major amputation as indicated); (ii)
primary (major amputation); (iii) bypass with up to five
surgical revisions or amputation as needed/indicated; (iv)
bypass with up to five endovascular interventions or
amputation as needed/indicated; and (v) endovascular
intervention with bypass for failure and up to four addi-
tional bypass revisions or amputation as needed/indicated.
A probabilistic Markov model was developed, with 19
health states to evaluate strategies. When compared with
strategy (i), the most cost-effective interventions were (iv)
at $US47,738/QALY followed by (iii) at $US58,749/
QALY. Strategy (ii)—primary amputation—was domi-
nated, costing over $US100,000 for every negative QALY,
meaning negative benefits and higher costs. Weaknesses of
the study included the lack of the hypothetical population
characteristics; absence of detailed unit costs and quanti-
ties; and no model calibration or validation details. A
particular strength of the study was the overall model
structure used to evaluate the five strategies.
3.4.6 Mathiesen et al. (Strength of Evidence: Low; Not
Recommended)
The last model-based study in this systematic review was
conducted by Mathiesen et al. [41] and addressed the
prevention of hospital-acquired pressure ulcers (HAPUs)
in Denmark. This cost-effectiveness study had a time
horizon of 1 year and the perspective of a healthcare
provider. It compared the Danish pressure ulcer bundle
(PUB), which comprises risk assessment, daily assessment
for patients at risk of developing a PU, nutrition assess-
ment for at-risk patients, and optimal mobilization with
decompression following repositioning for at-risk patients
with current standard of care. A decision analytic model
with seven health states was utilized to analyze cost
effectiveness. While explicit ICER values were only
available in graphic form, calculations indicate an ICER
of €415 per PU averted. Weaknesses of the study included
lack of separate reporting for resource quantities and
units; missing cost categories (only labor costs were cal-




4.1.1 Model Structure and Assumptions
Model structure, and the rationale/assumptions used to
create it are critical for any study that employs a model to
evaluate interventions or strategies. Although it can be
difficult to simulate real-life pathologies, the model should
be detailed enough to capture all major sequiturs likely to
have an impact and discuss reasons why any relevant
pathology-related health states are not included [45]. While
the majority of the studies reviewed had reasonable trees or
model structure, the decision tree or Markov model
employed in several studies was unclear as the graphics
presented were often a summary rather than a detailed tree
[32, 34, 37, 39].
Although hypothetical cohorts were used in all studies
utilizing decision trees or models, it was not always clear
what the demographics of such populations were. For
example, in the study conducted by Barshes et al. [40], it is
not known whether this model would be valid for elderly
patients, where the purely endovascular approach is often
preferable due to higher risk of surgical mortality [46].
4.1.2 Model Validation and Calibration
In the field of cardiology Haji et al. [47] noted that the
majority of model-based studies lacked validation and
calibration; this also appears to be true in the field of
wound care. With the exception of two studies [37, 39] in
which a serious attempt was made to report model cali-
bration and validity, little [36] or no information [34, 38,
40] was found in other Markov-based studies. This is one
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reason why only two model-based studies were given a
high strength of evidence rating.
None of the studies attempted cross-model validation.
While this can be construed as a weakness, in wound care
there may be an insufficient number of good models from
which to choose that encompass the particular pathologies,
settings, and details needed to make a reasonable match.
4.1.3 Credibility of Data Sources
In wound care, having several robust data sources for
outcomes is a common issue. One particular problem is
that using data from RCTs may be too biased because such
data do not reflect ‘real world’ situations [48]. The con-
verse dilemma is that there is a dearth of good observa-
tional studies that are appropriately powered and for which
outcomes have been adjusted for confounding variables, a
recommendation endorsed by the International Society for
Pharmacoeconomics and Outcomes Research (ISPOR)
[45]. A few studies, including trial-based studies, did not
report outcomes adequately, did not identify sources
properly, or did not specify how outcomes were derived for
model inputs [25, 31, 41].
Several studies [25–29, 31–33, 36, 44] did not report a
detailed breakdown of costs, the reference year for pricing,
or unit costs separately from quantities of resources used,
all of which are needed to assess adequacy of cost com-
pilation [49]. Moreover, some omitted relevant items could
have impacted reported results [26, 32, 33, 36, 41].
4.1.4 Indirect Costs
Only three studies attempted to capture indirect costs by
using a societal perspective [30, 38, 40], but in only one
study [40] were such costs likely to be representative.
Although the health provider cost perspective is a logical
choice for most studies, because the decision maker is
often the healthcare provider, such a perspective cannot
inform whether a particular intervention benefits society as
a whole, a detraction in the opinion of some health econ-
omists [50].
4.1.5 Time Horizon
All the trial-based studies had a time horizon of 1 year or
less, with the exception of the study by Makai et al. [34],
which was 2 years. Conversely, most of the model-based
studies had time horizons of the cohorts’ expected lifespan,
which varied considerably; one study [41] had a time
horizon of less than 1 year, albeit unclear, and one was
10 years [40].
While modeling longer time horizons can be challenging
because of sparse or inaccurate data, with appropriate
sensitivity analysis, uncertainties in results can be quanti-
fied to test assumptions. Studies carried out with short
horizon times, on the other hand, can produce misleading
results because we do not know the long-term effect of
interventions in the framework of cost effectiveness [51].
The conclusions of such studies should be regarded with
circumspection. Modeling longer horizon times also
requires realistic data for different time periods and for
different types of patients, which may not be available.
Merely extrapolating a year’s worth of modeled data can be
misleading as exemplified by the study by Padula et al.
[38], in which repeat hospitalizations were omitted, thereby
creating much unquantifiable uncertainty over the results.
The premise of the author’s argument was to extrapolate
the benefits of a better strategy for prevention and treat-
ment of PUs incurred during a single hospitalization epi-
sode that was modeled for 1 year over the remaining
patients’ lifespan. Based on a mean patient age of 56 years,
this is unrealistic as many patients would be likely to
undergo further hospitalization episodes. A better approach
would have been an undiscounted utility reward accumu-
lated over the 1 year or provision for a hospitalization
readmission pathway in the model structure, with the final
utility reward being accumulated over the patients’ esti-
mated lifespan.
4.1.6 Units of Effectiveness
Five of the model-based studies and one trial-based study
used QALYs or QALDs [34, 36–40]. Although this unit is
not an ideal effectiveness unit [52] and requires assessment
of utilities, which for some chronic wounds can be a
challenge, it does enable cost effectiveness of studies to be
compared against each other. The remaining studies either
used ulcer-free weeks or months (or calculations were
made in these units) or progressively more obscure effec-
tiveness units, which meant that most of the ICERs or
INHBs could not easily be related to any other health
economic studies in wound care nor easily assessed against
any common cost-effectiveness benchmarks.
4.2 Strengths and Limitations of the Present Study
A major strength of this systematic review is that included
studies were subject to rigorous quality review, and the
assessment paralleled the GRADE approach where feasi-
ble. A second strength of this review is that it followed
Preferred Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA) guidelines, although some
guidelines could not be applied due to the nature of the
study. In terms of limitations, it is possible that some
economic studies might have been missed because they
were published in languages other than English or were not
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cited in the searched databases. Second, studies are subject
to some judgment bias, even when using a comprehensive
appraisal system and it is possible that some studies might
be evaluated slightly differently.
4.3 Conclusions
Few well conducted cost-effectiveness studies exist that
can be used to guide decision makers in the field of chronic
wounds when the intervention is strategic in nature or is
based on guidelines. Although some evidence exists that it
is more cost effective to treat VLUs in specialized (wound
care) clinics, elements of organization and training need to
be better analyzed in the cost-effectiveness context. For
diabetic patients, one well executed model-based study
demonstrated that intensive glycemic control in conjunc-
tion with optimal foot care was cost effective over patients’
remaining lifespan; the strength of the evidence was
moderate. There is also good evidence that certain inter-
ventions are cost effective as part of a strategic approach to
prevent PUs in long-term care settings; however, in acute-
care facilities, similar approaches have yet to demonstrate
cost effectiveness. Finally, one other study demonstrated
clear cost-effective differences in approaches to treating
patients with CLI, but patient characteristics must also be
taken into consideration.
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